Topic: Labopharm Inc.
Labopharm Inc. said Wednesday it received marketing approval for its antidepressant Oleptro, a once-per-day version of a depression drug that is usually given twice a day.. The Canadian drugmaker said Oleptro was approved to treat major depressive disorder in adults. Labopharm said ...
FDA will not approve antidepressant application in present form, cites manufacturing deficienciesShares of Quebec-based Labopharm (TSX: Labopharm notes that the API manufacturer, Angelini, has said that the observations raised by the FDA are not critical and that it has not been questioned ...
Labopharm Inc. today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. ...
Labopharm Inc. today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. ...
